As of 2025-09-18, the Fair Value of Ultragenyx Pharmaceutical Inc (RARE) is -27.65 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 28.71 USD, the upside of Ultragenyx Pharmaceutical Inc is -196.31%.
With the market price of 28.71 USD and our fair value calculation, Ultragenyx Pharmaceutical Inc (RARE) is not a good investment. Investing in RARE stocks now will result in a potential loss of 196.31%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -186.60 | -454.00 | -707.40 | -606.64 | -569.18 | -504.76 |
| YoY growth | 53.66% | -143.30% | -55.81% | 14.24% | 6.17% | -25.01% |
| Market Cap (mil) | 2,766.78 |
| P/E | |
| Forward P/E |
| EPS | -5.53 |
| Avg earnings growth rate | -25.01% |
| TTM earnings | -532.93 |